{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T22:24:50Z","timestamp":1770330290134,"version":"3.49.0"},"reference-count":21,"publisher":"Oceanside Publications Inc.","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["allergy asthma proc"],"published-print":{"date-parts":[[2025,7,1]]},"abstract":"Background:<\/jats:bold> Delayed pressure urticaria (DpU) is a subtype of inducible urticaria characterized by painful erythematous swellings that appear after pressure is applied to the skin. Objectives:<\/jats:bold> The aim of this study was to evaluate the efficacy of omalizumab\n treatment in patients with DpU and the effect of omalizumab treatment on disease control. Methods:<\/jats:bold> This retrospective observational study included a total of 78 patients with chronic spontaneous urticaria (CSU) or DpU who received omalizumab treatment. At 6 months after\n the initiation of omalizumab treatment, the effects of the treatment on the the urticaria control test (UCT) and the Dermatology Quality of Life questionnaire (DLQI) score and the effects on pressure urticaria were evaluated. The effect of omalizumab on pressure urticaria was determined by\n performing a pressure provocation test. Results:<\/jats:bold> At the end of the 6th month of omalizumab treatment, the increase in UCT scores was statistically significant in all the patients, in the patients with CSU, and in the patients with CSU plus DpU (p\u2009<\u20090.001,\n p\u2009=\u20090.025, and p\u2009<\u20090.001, respectively). At the end of the 6th month of omalizumab treatment, the improvement in DLQI scores was statistically significant in all the patients, in patients with CSU, and in patients with CSU plus DpU (p\u2009<\u20090.001,\n p\u2009=\u20090.002, and p\u2009<\u20090.001, respectively). After the pressure provocation test, no urticarial wheals were observed in the area where pressure had been applied in any patient within 6 hours. Conclusion:<\/jats:bold> The findings of the current study provide\n evidence that omalizumab treatment may be effective in patients with DpU.<\/jats:p>","DOI":"10.2500\/aap.2025.46.250031","type":"journal-article","created":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T00:34:02Z","timestamp":1751934842000},"page":"323-327","source":"Crossref","is-referenced-by-count":2,"title":["Delayed pressure urticaria successfully treated with omalizumab: A tertiary-level health-care center experience"],"prefix":"10.2500","volume":"46","author":[{"given":"Mehmet Erdem","family":"Cakmak","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nida","family":"Oztop","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1355","reference":[{"key":"B1","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1684\/ejd.2019.3674","article-title":"Chronic urticaria phenotypes: clinical differences regarding triggers, activity, prognosis and therapeutic response","volume":"29","author":"Curto-Barredo","year":"2019","journal-title":"Eur J Dermatol"},{"key":"B2","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/all.15090","article-title":"The international EAACI\/GA2LEN\/EuroGuiDerm\/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria","volume":"77","author":"Zuberbier","year":"2022","journal-title":"Allergy"},{"key":"B3","first-page":"141","article-title":"Chronic inducible urticaria: classification and prominent features of physical and non-physical types","volume":"29","author":"Pozderac","year":"2020","journal-title":"Acta Dermatovenerol Alp Pannonica Adriat"},{"key":"B4","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1016\/j.jaip.2020.03.004","article-title":"Delayed pressure urticaria: a systematic review of treatment options","volume":"8","author":"Kulthanan","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B5","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/all.14547","article-title":"Efficacy and safety of treatment with omalizumab for chronic spontaneous urticaria: a systematic review for the EAACI Biologicals Guidelines","volume":"76","author":"Agache","year":"2021","journal-title":"Allergy"},{"key":"B6","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/bjd.19425","article-title":"Omalizumab for the treatment of chronic inducible urticaria in 80 patients","volume":"184","author":"Exposito-Serrano","year":"2021","journal-title":"Br J Dermatol"},{"key":"B7","doi-asserted-by":"crossref","first-page":"100501","DOI":"10.1016\/j.waojou.2020.100501","article-title":"Omalizumab treatment and outcomes in Chinese patients with chronic spontaneous urticaria, chronic inducible urticaria, or both","volume":"14","author":"Chen","year":"2021","journal-title":"World Allergy Organ J"},{"key":"B8","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1016\/j.jaip.2021.04.034","article-title":"Effectiveness and tolerability of personalized omalizumab treatment in patients with chronic inducible urticaria","volume":"9","author":"Buters","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B9","doi-asserted-by":"crossref","first-page":"82","DOI":"10.4274\/turkderm.22438","article-title":"The Turkish guideline for the diagnosis and management of urticaria","volume":"50","author":"G\u00f6nc\u00fc","year":"2016","journal-title":"Turkderm"},{"key":"B10","first-page":"997","article-title":"The Dermatology Life Quality Index 1994-2007: a comprehensive review of validation data and clinical results","volume":"159","author":"Basra","year":"2008","journal-title":"Br J Dermatol"},{"key":"B11","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1159\/000524887","article-title":"Delayed pressure urticaria: clinical and diagnostic features and response to omalizumab","volume":"183","author":"Veleiro-P\u00e9rez","year":"2022","journal-title":"Int Arch Allergy Immunol"},{"key":"B12","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.annder.2021.04.010","article-title":"Omalizumab in chronic inducible urticaria: a retrospective, real-life study","volume":"148","author":"Fialek","year":"2021","journal-title":"Ann Dermatol Venereol"},{"key":"B13","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jdermsci.2013.08.011","article-title":"Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: a retrospective clinical analysis","volume":"73","author":"Metz","year":"2014","journal-title":"J Dermatol Sci"},{"key":"B14","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1001\/jamadermatol.2013.8705","article-title":"Retreatment with omalizumab results in rapid remission in chronic spontaneous and inducible urticaria","volume":"150","author":"Metz","year":"2014","journal-title":"JAMA Dermatol"},{"key":"B15","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/bjd.14540","article-title":"Effectiveness and safety of omalizumab in chronic spontaneous or inducible urticaria: evaluation of 154 patients","volume":"175","author":"Ghazanfar","year":"2016","journal-title":"Br J Dermatol"},{"key":"B16","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1111\/ced.13173","article-title":"Long-term management of chronic spontaneous urticaria with omalizumab","volume":"42","author":"Pinto Gouveia","year":"2017","journal-title":"Clin Exp Dermatol"},{"key":"B17","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jaip.2016.07.016","article-title":"Rapid response to omalizumab in 3 cases of delayed pressure urticaria","volume":"5","author":"Quintero","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B18","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1111\/jocd.13764","article-title":"Successful treatment of delayed pressure urticaria with 300 mg of omalizumab every 14 days","volume":"20","author":"Saylam Kurtipek","year":"2021","journal-title":"J Cosmet Dermatol"},{"key":"B19","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1007\/s12016-017-8628-1","article-title":"Urticaria and angioedema: an update on classification and pathogenesis","volume":"54","author":"Radonjic-Hoesli","year":"2018","journal-title":"Clin Rev Allergy Immunol"},{"key":"B20","doi-asserted-by":"crossref","first-page":"416","DOI":"10.2340\/00015555-2224","article-title":"Bullous delayed pressure urticaria responding to omalizumab","volume":"96","author":"M\u00fcller","year":"2016","journal-title":"Acta Derm Venereol"},{"key":"B21","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/j.jaci.2006.02.028","article-title":"Effect of omalizumab treatment on peripheral eosinophil and T-lymphocyte function in patients with allergic asthma","volume":"117","author":"Noga","year":"2006","journal-title":"J Allergy Clin Immunol"}],"container-title":["Allergy and Asthma Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ingentaconnect.com\/content\/ocean\/aap\/2025\/00000046\/00000004\/art00009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T04:33:08Z","timestamp":1752553988000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ingentaconnect.com\/content\/10.2500\/aap.2025.46.250031"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,7,1]]}},"alternative-id":["1088-5412(20250701)46:4L.323;1-"],"URL":"https:\/\/doi.org\/10.2500\/aap.2025.46.250031","relation":{},"ISSN":["1088-5412"],"issn-type":[{"value":"1088-5412","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7,1]]}}}